UNSPSC 51373442: Codeine/guaifenesin/phenylpropanolamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373442 Codeine/guaifenesin/phenylpropanolamine is a Commodity code that does not align with the actual state and local procurement activity currently tagged under it. The recent solicitations posted against this code concern naloxone (an opioid antagonist), safe drug deactivation systems, and generic multi-source pharmaceuticals and over-the-counter products — none of which fall within the scope of the code's nominal product (a cough suppressant and decongestant combination). State and local governments do procure pharmaceuticals and related health products through competitive bidding and cooperative purchasing vehicles, but the specific products being solicited under this code number do not match its definition, making the code itself an unreliable signal for pursuit decisions in these categories.

The two recent opportunities show the breadth of actual pharmaceutical procurement across state and local jurisdictions. Seminole County, Florida issued an IFB (IFB60459723LAS) on June 30, 2026, to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a broader RFP (S1070000015802) with a deadline of March 26, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products across participating state and local facilities including Oregon, with contracts effective July 1, 2026. Both solicitations require vendor compliance with federal regulations, insurance, and specific manufacturing or supply-chain certifications. Without alignment between the code definition and the work being bought, this code shows little practical utility for targeting pharmaceutical procurement activity in state and local markets.